Genomic alterations in non–small cell lung cancer, breast cancer, and colorectal cancer. Genomic alterations in non–small cell lung cancer, breast cancer,

Slides:



Advertisements
Similar presentations
Cancer and Gene Regulation Chapter 18, Section 5.
Advertisements

Cell Cycle and Cancer.
Mutational analysis of 35 bladder cancer cell lines using RNA-seq.
Lecture 28 Genetics of Cancer Copyright © 2010 Pearson Education Inc.
Cancer Genome Landscapes
Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,
PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.
Lecture #8 Date _________
Cancer.
Gatekeeper, caretaker, and landscaper mutations
Cancer.
Clinical trial matching.
Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
سرطان الثدي Breast Cancer
The Genomics of Cancer and Molecular Testing:
A B C Supplementary figure S7
Lecture #8 Date _________
Landscape overview of GENIE dataset.
Metastasis gets site specific
Mutations and Genetic Abnormalities
Heatmaps of the gene mutation distributions in oncogene‐signaling blocks for six representative cancer types. Heatmaps of the gene mutation distributions.
BIOLOGY 12 Cancer.
Volume 74, Issue 5, Pages (November 2018)
Genomic alterations in breast cancer cell line MDA-MB-231.
Volume 27, Issue 3, Pages (March 2015)
Intrinsic and acquired trastuzumab resistance.
Copy-number alterations in an archival breast cancer sample.
Potential clinical actionability.
High-throughput analysis of informative CpG sites for the four studied tumor suppressor genes (A-D). High-throughput analysis of informative CpG sites.
How will cancer be treated in the 21st century?
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Diverse abnormalities manifest in RNA
Microarray analysis of phospho-Twist1–responsive genes.
Volume 151, Issue 2, Pages e6 (August 2016)
Volume 22, Issue 1, Pages (January 2018)
Volume 29, Issue 5, Pages (May 2016)
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer  Zengliu Su, Dora Dias-Santagata,
Robustness of TRU, Proximal-proliferative (PP), and Proximal-inflammatory (PI) classification. Robustness of TRU, Proximal-proliferative (PP), and Proximal-inflammatory.
Genetic Damage and Mutation
Specific Tumor Suppressor Genes
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Genetics of hepatocellular carcinoma: The next generation
Frequent alterations identified and potential actionability.
Mark I. Block, MD  The Annals of Thoracic Surgery 
MPM cases with GNH. A, WES-based LOH profiling with the FACETS algorithm revealed three MPM samples with genome-wide LOH. B, Allelic copy-number plots.
CREBBP loss-of-function results in gene expression repression signature. CREBBP loss-of-function results in gene expression repression signature. A–D,
Gene expression profiles of T cells.
The long tail of mutational hotspots in cancer.
Location of the ER mutations and frequencies per cohort.
Frequently mutated genes in colorectal cancer.
Molecular definitions of lung adenocarcinoma subtypes.
Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.
BRD4 expression and genomic distribution in B-CLL.
Identification of RASA1- and NF1-mutated lung cancer cell lines in the CCLE dataset (accessed via the cBioPortal for Cancer Genomics at
Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.
Germline variants influencing primary tumor type.
A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.
Single-cell analysis uncovers ductal cell subpopulations in human PDAC
Mutational signature analysis of WES data from patients with advanced PDAC. A, Projection of signatures representing four main mutational processes identified.
The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.
A variety of ROS1 gene fusions occur across multiple tumor types.
High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.
Driver pathways and key genes in OSCC
CASP8 mutations are associated with fewer CNAs and RAS family mutations. CASP8 mutations are associated with fewer CNAs and RAS family mutations. A, number.
Integrated analysis of gene expression and copy number alterations.
Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.
Molecular characterization of esophagogastric tumors.
Synthetic lethality of ROS1 inhibition in E-cadherin–deficient breast tumor cell lines. Synthetic lethality of ROS1 inhibition in E-cadherin–deficient.
Comparison of shRNA scoring approaches.
Presentation transcript:

Genomic alterations in non–small cell lung cancer, breast cancer, and colorectal cancer. Genomic alterations in non–small cell lung cancer, breast cancer, and colorectal cancer. A–C, The genomic alteration rate (including mutation, copy number, and rearrangement) aggregated to the gene level across the cohort for the top three most common tumor types is shown: non–small cell lung cancer, colorectal cancer, and breast cancer (A–C, respectively). Data for each center are shown as percentage of samples from that center with genomic alterations in a given gene. Directly adjacent to the main heat map is the proportional breakdown of the types of genomic alterations observed, and characterization of the mutation distribution observed in a given gene as oncogene and tumor suppressor, based on the normalized entropy (log2(N)-∑pilog2(pi), where N is the number of unique mutations in a given gene and pi is the proportion of mutations accounted for by a given unique mutation of a given gene) in the mutation spectrum and the prevalence of truncating and frameshift mutations, respectively. These data are limited to the gene with either: (i) 15% genomic alteration rate in at least one center, (ii) 5% genomic alteration rate in at least three centers, and (iii) OncoKB level 1 or 2A evidence for the tumor types shown. The “nc” designation in the colorbar legend indicates no coverage. The AACR Project GENIE Consortium Cancer Discov 2017;7:818-831 ©2017 by American Association for Cancer Research